Extension of Time to File SOU

MODUAX

Eli Lilly and Company

Request for Extension of Time to File a Statement of Use

PTO Form 1581 (Rev 9/2005)
OMB No. 0651-0054 (Exp. 10/31/2017)

Request for Extension of Time to File a Statement of Use
(15 U.S.C. Section 1051(d))


The table below presents the data as entered.

Input Field
Entered
SERIAL NUMBER 85476610
LAW OFFICE ASSIGNED LAW OFFICE 103
MARK SECTION
MARK MODUAX
STANDARD CHARACTERS YES
USPTO-GENERATED IMAGE YES
LITERAL ELEMENT MODUAX
OWNER SECTION
NAME Eli Lilly and Company
STREET Lilly Corporate Center
CITY Indianapolis
STATE Indiana
ZIP/POSTAL CODE 46285
COUNTRY United States
PHONE 317-276-9624
FAX 317-276-1919
EMAIL XXXX
GOODS AND/OR SERVICES SECTION
INTERNATIONAL CLASS 005
CURRENT IDENTIFICATION Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorders, Alzheimer's, anxiety disorders, atherosclerosis, autoimmune diseases and disorders, blood disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cholesterol disorders, cystic fibrosis, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders, inflammation and inflammatory diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, migraines, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, pancreatic diseases and disorders, psychiatric disorders, reproductive system diseases and disorders, sleep disorders, urological disorders; antipsychotic pharmaceutical preparations; antidepressants
GOODS OR SERVICES DELETED FROM THE APPLICATION reproductive system diseases and disorders,
GOODS OR SERVICES FOR WHICH APPLICANT HAS A CONTINUED BONA FIDE INTENTION, AND IS ENTITLED, TO USE Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorders, Alzheimer's, anxiety disorders, atherosclerosis, autoimmune diseases and disorders, blood disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cholesterol disorders, cystic fibrosis, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders, inflammation and inflammatory diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, migraines, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, pancreatic diseases and disorders, psychiatric disorders, sleep disorders, urological disorders; antipsychotic pharmaceutical preparations; antidepressants
EXTENSION SECTION
EXTENSION NUMBER 5
ONGOING EFFORT product or service research or development
ALLOWANCE MAIL DATE 06/18/2013
STATEMENT OF USE NO
PAYMENT SECTION
NUMBER OF CLASSES 1
SUBTOTAL AMOUNT 150
TOTAL AMOUNT 150
SIGNATURE SECTION
SIGNATURE /blongbottom/
SIGNATORY'S NAME Bruce W. Longbottom
SIGNATORY'S POSITION Assistant General Counsel
DATE SIGNED 09/17/2015
SIGNATORY'S PHONE NUMBER 317-651-1346
FILING INFORMATION
SUBMIT DATE Thu Sep 17 15:50:17 EDT 2015
TEAS STAMP USPTO/ESU-XX.X.XX.XX-2015
0917155017565213-85476610
-5409850fa64cd15a53d39e9d
b01c56f64b4b9ef55bad4e1e7
2b44b5cd68e9c25-DA-2361-2
0150917144739418774



PTO Form 1581 (Rev 9/2005)
OMB No. 0651-0054 (Exp. 10/31/2017)


SOU Extension Request
(15 U.S.C. Section 1051(d))


To the Commissioner for Trademarks:

MARK: MODUAX
SERIAL NUMBER: 85476610

The applicant, Eli Lilly and Company, having an address of
      Lilly Corporate Center
      Indianapolis, Indiana 46285
      United States
requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application.    The Notice of Allowance mailing date was 06/18/2013.

For International Class 005:
Current identification: Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorders, Alzheimer's, anxiety disorders, atherosclerosis, autoimmune diseases and disorders, blood disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cholesterol disorders, cystic fibrosis, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders, inflammation and inflammatory diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, migraines, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, pancreatic diseases and disorders, psychiatric disorders, reproductive system diseases and disorders, sleep disorders, urological disorders; antipsychotic pharmaceutical preparations; antidepressants

This filing does NOT cover the following goods/services listed in either the application or Notice of Allowance or as subsequently modified for this specific class; these goods/services are permanently deleted from this application: reproductive system diseases and disorders,

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class: Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorders, Alzheimer's, anxiety disorders, atherosclerosis, autoimmune diseases and disorders, blood disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cholesterol disorders, cystic fibrosis, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders, inflammation and inflammatory diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, migraines, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, pancreatic diseases and disorders, psychiatric disorders, sleep disorders, urological disorders; antipsychotic pharmaceutical preparations; antidepressants

This is the fifth extension request. The applicant has made the following ongoing efforts to use the mark in commerce on or in connection with each of those goods/services covered by the extension request: product or service research or development



A fee payment in the amount of $150 will be submitted with the form, representing payment for 1 class.


Declaration

STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section 1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.

DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made on information and belief are believed to be true.


Signature: /blongbottom/      Date Signed: 09/17/2015
Signatory's Name: Bruce W. Longbottom
Signatory's Position: Assistant General Counsel
Signatory's Phone: 317-651-1346

RAM Sale Number: 85476610
RAM Accounting Date: 09/18/2015

Serial Number: 85476610
Internet Transmission Date: Thu Sep 17 15:50:17 EDT 2015
TEAS Stamp: USPTO/ESU-XX.X.XX.XX-2015091715501756521
3-85476610-5409850fa64cd15a53d39e9db01c5
6f64b4b9ef55bad4e1e72b44b5cd68e9c25-DA-2
361-20150917144739418774



Extension of Time to File SOU [image/jpeg]


uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed